Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / THBS1

THBS1

Basics

Aliases:
This biomarker is also known as:
  • TSP-1,
  • thrombospondin-1p180,
  • THBS-1,
  • TSP,
  • THBS,
  • Thrombospondin-1,

View in BioMuta

Description…

TSP is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. TSP can bind to fibrinogen, fibronectin, laminin, type V collagen and integrins alpha-V/beta-1. It has been shown to play roles in platelet aggregation, angiogenesis, and tumorigenesis.

Attributes

QA State: Accepted
Type: Protein
Short Name:

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: Two
QA State: Accepted

Overview

Blood protein markers that provide more accurate or earlier diagnosis of prostate cancer should have a positive impact on prostate cancer treatment and management. Experimental evidence shows that thrombospondin-1 levels are elevated in patients with benign prostatic disease and repressed in patients with prostate cancer. Thrombospondin-1 levels do not correlate with prostate-specific antigen (PSA) levels and differentiate benign from malignant disease with 79% sensitivity and 81% specificity. The measurement of thrombospondin-1 could be used to assist the decision to obtain a biopsy in men with suspected prostate cancer, which could lead to a reduction in the number of unnecessary prostatic biopsies.

Performance Comment

TSP did not, for the populations tested in these experiments, show strong pre-diagnostic performance. This biomarker has not moved on to Phase 3 study.

Supporting Study Data

The following studies/protocols provide evidence supporting THBS1 indications for the Prostate…

Prostate Rapid Pre-Validation Set

Determine which markers move to validation using the prospectie prostate reference set samples.

View more about this study
Biomarker Characteristics Summary

No statistics found.

Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Prostate Rapid Reference Set Application: Haab - Van Andel (2006)

To evaluate TSP-1 as a marker to specifically detect prostate cancer

View more about this study
Biomarker Characteristics Summary
Notes Sensitivity Specificity Prevalence NPV PPV Specific Assay Type
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing cases with Gleason grade >=7 (n=30) to the pool of controls and cases with Gleason grade <7 (n=93), for the average of normalized TSP, AUC was 0.54 (0.42, 0.66). 90.0 13.0 N/A N/A N/A
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). For the average of unnormalized TSP, AUC was 0.52 (0.42, 0.62). 90.0 10.0 N/A N/A N/A
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). For the average of normalized TSP, AUC was 0.5 (0.4, 0.61). 90.0 5.0 N/A N/A N/A
Measured among 123 samples (60 controls and 63 cases). Among the cases, 33 had low Gleason grade (<7) and 30 had high Gleason grade (>=7). When comparing cases with Gleason grade >=7 (n=30) to the pool of controls and cases with Gleason grade <7 (n=93), for the average of unnormalized TSP, AUC was 0.53 (0.41, 0.66). 90.0 6.0 N/A N/A N/A
Decision Rule

No clinically useful decision rule found.

Additional Study-Specific Protocols
Study-Specific Publications

No study-specific publications defined.

Study-Specific Resources

No study-specific resources defined.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html